Sun Pharma, the leading pharmaceutical company in India, has announced its plans to acquire Checkpoint Therapeutics for $355 million. This move is aimed at bolstering Sun Pharma’s specialty portfolio, particularly with the addition of UNLOXCYT, an FDA-approved medication for advanced skin cancer. By acquiring Checkpoint Therapeutics, Sun Pharma is poised to expand its global footprint in the field of oncology treatments.